Literature DB >> 19822279

Multimodality management of malignant pleural mesothelioma: introduction.

David J Sugarbaker.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19822279     DOI： 10.1053/j.semtcvs.2009.07.005

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN： 1043-0679


× No keyword cloud information.
  4 in total

Review 1.  Lung cancer: Biology and treatment options.

Authors:  Hassan Lemjabbar-Alaoui; Omer Ui Hassan; Yi-Wei Yang; Petra Buchanan
Journal:  Biochim Biophys Acta       Date:  2015-08-19

Review 2.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

3.  Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.

Authors:  Xiaoqing He; Liying Wang; Heimo Riedel; Kai Wang; Yong Yang; Cerasela Zoica Dinu; Yon Rojanasakul
Journal:  Mol Cancer       Date:  2017-03-14       Impact factor: 27.401

4.  A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition.

Authors:  Mutsumi Hayashi; Hiroko Madokoro; Koji Yamada; Hiroko Nishida; Chikao Morimoto; Michiie Sakamoto; Taketo Yamada
Journal:  Cancer Cell Int       Date:  2016-04-30       Impact factor: 5.722
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.